AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9117178 — intervention group
Group type: COMPARATOR
Intervention: Ordinary omnivorous diets
Number of subjects: 43
Study 8482933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 417
Study 2950148 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 1 gram/day for 6 months plus topical therapy (benzoyl peroxide)
Number of subjects: 0
Study 2950148 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (2 mg cyproterone acetate plus 50 micrograms ethinyl estradiol; spironolactone 100 mg twice daily; isotretinoin 1 mg/kg)
Number of subjects: 0
Study 2950148 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 0
Study 31851382 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeled Practice
Number of subjects: 101
Study 31851382 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 101
Study 30528676 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04457845 (4 mg per day)
Number of subjects: 70
Study 30528676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 28049937 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated water-based exercise (HEx) training protocol (callisthenic exercises and walking in a heated pool for 1 h, three times weekly for 12 weeks)
Number of subjects: 44
Study 28049937 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintaining habitual activities)
Number of subjects: 44
Study 26527774 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 Gy
Number of subjects: 344
Study 26527774 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy
Number of subjects: 344
Study 23669629 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nicotine (placebo-controlled trial)
Number of subjects: 1649
Study 23669629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (patch vs spray, open-label trial)
Number of subjects: 1649
Study 23669629 — intervention group
Group type: COMPARATOR
Intervention: Bupropion (placebo-controlled trial)
Number of subjects: 1649
Study 23669629 — intervention group
Group type: EXPERIMENTAL
Intervention: No lapse during the first week (across all trials)
Number of subjects: 1649
Study 21080201 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (vinca alkaloids, taxanes, or platina derivatives)
Number of subjects: 152
Study 19333153 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine 0.5 mg and clonidine 100 microg (CMC)
Number of subjects: 85
Study 19333153 — intervention group
Group type: COMPARATOR
Intervention: Preservative free morphine 0.5 mg (MOR)
Number of subjects: 85
Study 16697968 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue (GnRH-a) injections during cyclophosphamide therapy
Number of subjects: 63
Study 16697968 — intervention group
Group type: COMPARATOR
Intervention: No injection of GnRH analogue (GnRH-a) during cyclophosphamide therapy
Number of subjects: 63
Study 14599857 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Ralstron applicator
Number of subjects: 50
Study 14599857 — intervention group
Group type: COMPARATOR
Intervention: Rigid geometry Rotterdam applicator
Number of subjects: 50
Study 10758454 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 6 microg kg‐1
Number of subjects: 40
Study 10758454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 40
Study 10758454 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg kg‐1
Number of subjects: 40
Study 10758454 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg kg‐1
Number of subjects: 40
Study 8993085 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (maximum dose 225 mg/day)
Number of subjects: 0
Study 8993085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8993085 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 1479658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve blocks (Group A, n = 20)
Number of subjects: 40
Study 1479658 — intervention group
Group type: COMPARATOR
Intervention: No nerve blocks (Group B, n = 20)
Number of subjects: 40
Study 1479658 — intervention group
Group type: EXPERIMENTAL
Intervention: Crying-group (n = 9)
Number of subjects: 40
Study 1479658 — intervention group
Group type: EXPERIMENTAL
Intervention: Calm-group (n = 31)
Number of subjects: 40
Study 2865714 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin
Number of subjects: 0
Study 2865714 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 0
Study 2865714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 0
Study 2865714 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 2865714 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related induction
Number of subjects: 0
Study 30659771 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 30659771 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosage regimen and formulations
Number of subjects: 0
Study 29668978 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir + lamivudine
Number of subjects: 266
Study 29668978 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir + 2NRTI
Number of subjects: 266
Study 26663715 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC + EFV
Number of subjects: 0
Study 26663715 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC + ATV/r
Number of subjects: 0
Study 26663715 — intervention group
Group type: COMPARATOR
Intervention: ABC/3TC + EFV
Number of subjects: 0
Study 26663715 — intervention group
Group type: COMPARATOR
Intervention: ABC/3TC + ATV/r
Number of subjects: 0
Study 24559218 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced multi-disciplinary teams (EMDTs)
Number of subjects: 137
Study 24559218 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 137
Study 22541809 — intervention group
Group type: EXPERIMENTAL
Intervention: Push method
Number of subjects: 72
Study 22541809 — intervention group
Group type: COMPARATOR
Intervention: Pull method
Number of subjects: 72
Study 20609968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg
Number of subjects: 546
Study 20609968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 546
Study 20609968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 546
Study 20609968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study 20609968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (all doses)
Number of subjects: 546
Study 18514318 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall average RNFL thickness
Number of subjects: 89
Study 18514318 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior quadrant RNFL thickness
Number of subjects: 89
Study 18514318 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior quadrant RNFL thickness
Number of subjects: 89
Study 18514318 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of overall, inferior, and superior quadrant RNFL thicknesses
Number of subjects: 89
Study 16583592 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total
Number of subjects: 0
Study 16583592 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total plus Whitening
Number of subjects: 0
Study 16583592 — intervention group
Group type: EXPERIMENTAL
Intervention: PerioGard
Number of subjects: 0
Study 16583592 — intervention group
Group type: COMPARATOR
Intervention: Colgate Regular Dental Cream
Number of subjects: 0
Study 16583592 — intervention group
Group type: COMPARATOR
Intervention: Fluorigard
Number of subjects: 0
Study 11796444 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP, 800 microg/d
Number of subjects: 68
Study 11796444 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP, 1,500 microg/d
Number of subjects: 68
Study 10380867 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-detection approach in 3-year-olds
Number of subjects: 3
Study 10380867 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of puppet's behavior by 3-year-olds
Number of subjects: 3
Study 8696715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-mitomycin-vinorelbine (VNB group, n = 114)
Number of subjects: 227
Study 8696715 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-mitomycin-vindesine (VDS group, n = 113)
Number of subjects: 227
Study 8696715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-mitomycin-vinorelbine (VNB group)
Number of subjects: 227
Study 8696715 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-mitomycin-vindesine (VDS group)
Number of subjects: 227
Study 1508114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and intracoronary therapy with streptokinase
Number of subjects: 206
Study 1508114 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 206
Study 1508114 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 206
Study 1508114 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reperfusion (less than or equal to 3.5 h)
Number of subjects: 206
Study 1508114 — intervention group
Group type: COMPARATOR
Intervention: CABG patients
Number of subjects: 206
Study 1508114 — intervention group
Group type: COMPARATOR
Intervention: PTCA patients
Number of subjects: 206
Study 1508114 — intervention group
Group type: COMPARATOR
Intervention: Patients without reperfusion
Number of subjects: 206
Study 6389014 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine maleate (100 mg, oral doses, up to 4 doses per day for 5 days)
Number of subjects: 40
Study 6389014 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1 g, oral doses, up to 4 doses per day for 5 days)
Number of subjects: 40
Study 6389014 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine maleate
Number of subjects: 40
Study 6389014 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 40
Study 31621643 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC (work intervals with a fast start)
Number of subjects: 11
Study 31621643 — intervention group
Group type: COMPARATOR
Intervention: TRAD (traditional session with constant speed)
Number of subjects: 11
Study 29287749 — intervention group
Group type: EXPERIMENTAL
Intervention: Andecaliximab (400 mg) administered every 2 weeks for a total of 3 intravenous infusions.
Number of subjects: 18
Study 29287749 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered every 2 weeks for a total of 3 intravenous infusions.
Number of subjects: 18
Study 26550689 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral-valve repair
Number of subjects: 251
Study 26550689 — intervention group
Group type: COMPARATOR
Intervention: Mitral-valve replacement
Number of subjects: 251
Study 25020152 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based prevention program
Number of subjects: 107
Study 25020152 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based prevention program
Number of subjects: 107
Study 25020152 — intervention group
Group type: COMPARATOR
Intervention: Educational video and educational brochure
Number of subjects: 107
Study 22633825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate, 64 mmol/day
Number of subjects: 1204
Study 22633825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1204
Study 22633825 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (from meta-analysis)
Number of subjects: 1204
Study 19341900 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 7
Study 19341900 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-EVAR treatment)
Number of subjects: 7
Study 17929300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin for 72 hours prior to peginterferon alpha‐2a injection
Number of subjects: 0
Study 17929300 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha‐2a for 24 hours prior to biopsy
Number of subjects: 0
Study 17929300 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment group (matched control)
Number of subjects: 0
Study 17929300 — intervention group
Group type: EXPERIMENTAL
Intervention: On treatment (RRs and SRs)
Number of subjects: 0
Study 15164894 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior sleep restriction condition (6 hours sleep per day for 7 days)
Number of subjects: 21
Study 15164894 — intervention group
Group type: COMPARATOR
Intervention: Prior sleep extension condition (12 hours sleep per day for 7 days)
Number of subjects: 21
Study 15164894 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobehavioral testing during 36 hours of total sleep deprivation
Number of subjects: 21
Study 10770145 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride (50 to 200 mg/d, starting at 25 mg/d)
Number of subjects: 187
Study 10770145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 9293218 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard behavioral multicomponent program of Becoña
Number of subjects: 75
Study 9293218 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention group (standard program + relapse prevention component)
Number of subjects: 75
Study 9293218 — intervention group
Group type: COMPARATOR
Intervention: Control group (information session only)
Number of subjects: 75
Study 8420682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal phosphorus-32
Number of subjects: 24
Study 8420682 — intervention group
Group type: COMPARATOR
Intervention: Three monthly cycles of cyclophosphamide and cisplatin
Number of subjects: 24
Study 3552699 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 3 g cephalexin
Number of subjects: 86
Study 3552699 — intervention group
Group type: COMPARATOR
Intervention: 3 days of cephalexin 1 g or combined preparation of pivmecillinam-pivampicillin
Number of subjects: 86
Study 2566825 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma treatment for lesions due to Leishmania braziliensis guyanensis
Number of subjects: 26
Study 2566825 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma treatment for lesions due to Leishmania tropica
Number of subjects: 26
Study 2566825 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma treatment
Number of subjects: 26
Study 2566825 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological and immunohistochemical studies
Number of subjects: 26
Study 31984406 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro total analysis system (μTAS) based on electrochemical measurements and dielectrophoretic sorting for screening of NAD(P)‐dependent oxidoreductases; specific details on dosage and duration not available.
Number of subjects: 0
Study 31984406 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron-doped diamond (BDD) electrode for high-throughput measurement of enzyme activity; specific details on dosage and duration not available.
Number of subjects: 0
Study 31415008 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 0
Study 31415008 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aromatherapy)
Number of subjects: 0
Study 28852842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nutraceutical supplement (one daily tablet containing phytoestrogens, vitamins, micronutrients, and passion flower herbal medicine) for 6 months
Number of subjects: 90
Study 28852842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nutraceutical supplement
Number of subjects: 90
Study 28852842 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study 25274038 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening every 4 years (cut-off 4 ng/ml)
Number of subjects: 80
Study 24144057 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine (15 g/day)
Number of subjects: 60
Study 24144057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21338741 — intervention group
Group type: EXPERIMENTAL
Intervention: Large portion size (300 g)
Number of subjects: 17
Study 21338741 — intervention group
Group type: EXPERIMENTAL
Intervention: Small portion size (150 g)
Number of subjects: 17
Study 19687576 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta monotherapy for < or = 24 weeks
Number of subjects: 31
Study 17005085 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaixin Capsule (KXC) in combination with conventional Western medicine
Number of subjects: 72
Study 17005085 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine (Control)
Number of subjects: 72
Study 17005085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (KXC and Control)
Number of subjects: 72
Study 15546056 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute day hospital treatment (87.7 days)
Number of subjects: 191
Study 15546056 — intervention group
Group type: COMPARATOR
Intervention: Conventional inpatient treatment (67.8 days)
Number of subjects: 191
Study 11025891 — intervention group
Group type: EXPERIMENTAL
Intervention: Autocapture On (Group I, 81 patients)
Number of subjects: 162
Study 11025891 — intervention group
Group type: COMPARATOR
Intervention: Autocapture Off (Group II, 81 patients)
Number of subjects: 162
Study 9570378 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP
Number of subjects: 85
Study 9570378 — intervention group
Group type: COMPARATOR
Intervention: PE
Number of subjects: 85
Study 8447244 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose lithium
Number of subjects: 24
Study 8447244 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily dose lithium
Number of subjects: 24
Study 3533265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg daily for five weeks)
Number of subjects: 26
Study 3533265 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.25 mg daily for five weeks)
Number of subjects: 26
Study 30567725 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/m2 of IV decitabine on days 1 to 10 for up to 4 10-day cycles followed by monthly 5-day cycles
Number of subjects: 64
Study 27311915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (KE)
Number of subjects: 57
Study 27311915 — intervention group
Group type: COMPARATOR
Intervention: Conventional anaesthetics (high dose midazolam, thiopental and/or propofol)
Number of subjects: 57
Study 25855109 — intervention group
Group type: EXPERIMENTAL
Intervention: Home self administration of vaginal misoprostol (800 mcg)
Number of subjects: 188
Study 25855109 — intervention group
Group type: COMPARATOR
Intervention: Hospital administration of vaginal misoprostol (800 mcg)
Number of subjects: 188
Study 25855109 — intervention group
Group type: EXPERIMENTAL
Intervention: Home self administration of vaginal misoprostol (800 mcg) after 2nd dose (400 mcg)
Number of subjects: 188
Study 25855109 — intervention group
Group type: COMPARATOR
Intervention: Hospital administration of vaginal misoprostol (800 mcg) after 2nd dose (400 mcg)
Number of subjects: 188
Study 25855109 — intervention group
Group type: EXPERIMENTAL
Intervention: Home self administration of vaginal misoprostol
Number of subjects: 188
Study 25855109 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of extra dose of misoprostol
Number of subjects: 188
Study 22883359 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:5 diluted Buckley's formocresol (FC)
Number of subjects: 30
Study 22883359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper(®) (ABS)
Number of subjects: 30
Study 19536451 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 20
Study 19536451 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 20
Study 18772860 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 40
Study 18772860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from patients treated with nebivolol
Number of subjects: 40
Study 18772860 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 40
Study 16004737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led secondary prevention clinics
Number of subjects: 36
Study 12952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutter Frame with Supplemental Oxygen (GFSO)
Number of subjects: 110
Study 12952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutter Frame with Supplemental Air (GFSA)
Number of subjects: 110
Study 12952150 — intervention group
Group type: COMPARATOR
Intervention: Rollator with Supplemental Air (RSA)
Number of subjects: 110
Study 12952150 — intervention group
Group type: COMPARATOR
Intervention: Rollator with Supplemental Oxygen (RSO)
Number of subjects: 110
Study 10698807 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 152
Study 10698807 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 152
Study 9379654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern reversal (pr) stimulation in group III (20 years and more)
Number of subjects: 90
Study 9379654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern flash (pf) stimulation in group III (20 years and more)
Number of subjects: 90
Study 9379654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern flash (pf) stimulation in group II (11-20 years)
Number of subjects: 90
Study 9379654 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 healthy age-matched males, not exposed to leaded petrol)
Number of subjects: 90
Study 8368548 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast injection (FI) of isobaric 0.5% bupivacaine (2 mL during 2 to 3 s or approximately 0.75 mL/s)
Number of subjects: 40
Study 8368548 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow injection (SI) of isobaric 0.5% bupivacaine (1 mL/min)
Number of subjects: 40
Study 8368548 — intervention group
Group type: COMPARATOR
Intervention: Fast reinjection (FI group) of isobaric 0.5% bupivacaine (10 mg, 2 mL)
Number of subjects: 40
Study 8368548 — intervention group
Group type: COMPARATOR
Intervention: Slow reinjection (SI group) of isobaric 0.5% bupivacaine (10 mg, 2 mL)
Number of subjects: 40
Study 8368548 — intervention group
Group type: COMPARATOR
Intervention: Duration of sensory block in FI group
Number of subjects: 40